Marumax

Tamsulosin Hydrochloride and Dutasteride, the active ingredient in Marumax, is an Alpha‑1 adrenergic antagonist and 5‑alpha‑reductase inhibitor presented as an oral tablet formulation for oral use. It is indicated for the management of benign prostatic hyperplasia in adult men. GNH USA supplies Marumax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Marumax combines two agents that act on the prostate and lower urinary tract to relieve obstruction caused by benign prostatic hyperplasia. - Benign prostatic hyperplasia (BPH): reduces urinary frequency, urgency and improves urine flow. - Lower urinary tract symptoms (LUTS) associated with BPH: alleviates nocturia and incomplete bladder emptying. - Prostate enlargement: decreases prostate volume over time, helping to prevent disease progression.

Marumax may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Dizziness or light‑headedness, especially on standing. - Ejaculatory dysfunction or reduced semen volume. - Decreased libido or sexual desire. - Headache. - Nasal congestion or runny nose. - Orthostatic hypotension.

Serious or Rare Side Effects: - Priapism (prolonged erection). - Severe hypotension leading to fainting. - Significant liver enzyme elevation. - Allergic reactions such as rash, itching or swelling. - Angioedema involving face, lips or throat. - Acute urinary retention in rare cases.

Before initiating Marumax, clinicians should evaluate patient‑specific factors and monitor for potential risks. - Assess cardiovascular status: monitor for hypotension, especially in patients on antihypertensives. - Review concomitant alpha‑blocker use: avoid additive blood‑pressure effects. - Check liver function: Dutasteride may affect hepatic enzymes. - Avoid in patients with known hypersensitivity to either component. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Marumax can interact with several medicines; some combinations should be avoided while others require careful monitoring.

Major Interactions (Avoid): - Other alpha‑1 blockers (e.g., prazosin): risk of severe hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase dutasteride exposure. - Warfarin: may enhance anticoagulant effect and bleeding risk.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood‑pressure lowering. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): may increase hypotensive episodes. - Rifampin or other CYP3A4 inducers: may reduce dutasteride effectiveness.